E.R. Squibb & Sons, L.L.C. received FDA approval for Iberdomide Hydrochloride, a novel oral lenalidomide analog, suggesting a potential for significant expansion of Squibb's market share in the liquid steroids market for multiple myeloma, contingent upon addressing potential safety concerns preceding the 2026 launch.